{
    "id": "1287590b-abdf-470b-a611-dfb9bc93692a",
    "indications": "Alogliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.",
    "contraindications": "The recommended dosage in patients with normal renal function or mild renal impairment is 25 mg orally once daily. ( 2.1 ) Can be taken with or without food. ( 2.1 ) Adjust dosage if moderate or severe renal impairment or end-stage renal disease (ESRD). ( 2.2 ) Degree of Renal Impairment Creatinine Clearance (mL/min) Recommended Dosage Moderate ≥30 to <60 12.5 mg once daily Severe/ESRD <30 6.25 mg once daily",
    "warningsAndPrecautions": "Alogliptin tablets are available as film-coated tablets containing 25 mg, 12.5 mg or 6.25 mg of alogliptin as follows:\n                  25 mg tablet: light red, oval, biconvex, film-coated, with \"TAK ALG-25\" printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                             NDC 45802-150-65\n                           Bottles of 30 tablets\n                        \n                     \n                  \n                  12.5 mg tablet: yellow, oval, biconvex, film-coated, with \"TAK ALG-12.5\" printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                             NDC 45802-103-65\n                           Bottles of 30 tablets\n                        \n                     \n                  \n                  6.25 mg tablet: light pink, oval, biconvex, film-coated, with \"TAK ALG-6.25\" printed on one side, available in:\n                  \n                     \n                     \n                     \n                        \n                             NDC 45802-087-65\n                           Bottles of 30 tablets",
    "adverseReactions": "Alogliptin tablets is contraindicated in patients with a history of serious hypersensitivity to alogliptin or any of the excipients in Alogliptin tablets. Reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have been reported [see Warnings and Precautions (5.3), Adverse Reactions (6.2)].",
    "ingredients": [
        {
            "name": "Alogliptin Benzoate",
            "code": "EEN99869SC"
        },
        {
            "name": "Mannitol",
            "code": "3OWL53L36A"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "Microcrystalline Cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "Croscarmellose sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "Titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "Polyethylene Glycol 8000",
            "code": "Q662QK8M3B"
        },
        {
            "name": "Ferric oxide Red",
            "code": "1K09F3G675"
        },
        {
            "name": "Ferrosoferric oxide",
            "code": "XM0M87F357"
        },
        {
            "name": "Shellac",
            "code": "46N107B71O"
        },
        {
            "name": "Butyl Alcohol",
            "code": "8PJ61P6TS3"
        },
        {
            "name": "Alcohol",
            "code": "3K9958V90M"
        },
        {
            "name": "Ferric oxide Yellow",
            "code": "EX438O2MRT"
        }
    ],
    "organization": "Padagis Israel Pharmaceuticals Ltd",
    "name": "Alogliptin",
    "effectiveTime": "20250411"
}